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It has previously been reported that mouse epiblast
stem cell (EpiSC) lines comprise heterogeneous cell
populations that are functionally equivalent to cells
of either early- or late-stage postimplantation devel-
opment. So far, the establishment of the embryonic
stem cell (ESC) pluripotency gene regulatory network
through the widely known chemical inhibition of MEK
and GSK3beta has been impractical in late-stage
EpiSCs. Here, we show that chemical inhibition of
casein kinase 1alpha (CK1alpha) induces the con-
version of recalcitrant late-stage EpiSCs into ESC
pluripotency. CK1alpha inhibition directly results in
the simultaneous activation of the WNT signaling
pathway, together with inhibition of the TGFbeta/
SMAD2 signaling pathway, mediating the rewiring
of the gene regulatory network in favor of an ESC-
like state. Our findings uncover a molecular mecha-
nism that links CK1alpha to ESC pluripotency
through the direct modulation of WNT and TGFbeta
signaling.
INTRODUCTION
Pluripotency is defined as a cell’s ability to differentiate into all
somatic cell types. Two different pluripotent cell states haveThis is an open access article under the CC BY-Nbeen proposed, which are commonly termed naı¨ve and primed
pluripotency. Mouse embryonic stem cells (ESCs) are derived
from the inner cell mass (ICM) of developing embryos and
have the ability to colonize preimplantation embryos after injec-
tion (Martin, 1981; Evans and Kaufman, 1981). This is a hallmark
feature of naive pluripotency, but such pluripotency is not neces-
sarily the first pluripotent state in development, as mouse ESCs
correspond to day-4.5 and not day-3.5 ICMs (Boroviak et al.,
2014). While scientists try to define the naive pluripotent state
in humans (Dodsworth et al., 2015), it appears that the culture
conditions of a pluripotent state corresponding to day-3.5
mouse embryos are yet to be defined.
In contrast to ESCs, epiblast stem cells (EpiSCs), which are
derived from the epiblast of postimplantation embryos, can
readily form teratomas and colonize embryos after being injected
into the postimplantation epiblast (Huang et al., 2012). However,
when cultured under standard conditions, EpiSCs rarely, if at all,
contribute to embryo development after being injected into pre-
implantation embryos (Brons et al., 2007; Tesar et al., 2007;
Han et al., 2010). These features are commonly considered to
be the hallmark of primed pluripotency.
EpiSCs depend on basic fibroblast growth factor (bFGF) and
Activin A signaling for maintaining pluripotency, while mouse
ESCs require LIF together with inhibition of GSK3beta and fibro-
blast growth factor/extracellular-signal-regulated kinase (FGF/
ERK). Mouse ESCs form small, compact, three-dimensional
colonies, whereas EpiSCs grow as large, flat colonies. A small
number of transcription factors that are highly expressed in
ESCs, but not in EpiSCs, have been found to reprogram EpiSCsCell Reports 15, 787–800, April 26, 2016 ª2016 The Authors 787
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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into ESCs (Tai and Ying, 2013; Gillich et al., 2012; Guo et al.,
2009; Silva et al., 2009; Guo and Smith, 2010; Hall et al., 2009;
Festuccia et al., 2012). Other studies have reported that the
expression of transgenes is not required, and that EpiSCs could
be converted into ESCs by a change in the culture conditions
alone (Bao et al., 2009; Greber et al., 2010; Hanna et al., 2009;
Chou et al., 2008; Ware et al., 2009).
The existence of at least one more distinct pluripotent state
was previously revealed by our study, showing that EpiSC cul-
tures display features of both early- and late-stage mouse epi-
blasts (Han et al., 2010). This work was prompted by the finding
that EpiSCs display heterogeneity within a population (Tsakiridis
et al., 2014; Han et al., 2010) and between different cell lines
(Bernemann et al., 2011). Part of this heterogeneity is probably
due to the broad developmental window of derivation. In this
regard, it has been suggested that early-stage EpiSCs are
susceptible to cellular reprogramming toward an ESC-like state,
whereas late-stage EpiSCs are recalcitrant to this process (Han
et al., 2010; Bernemann et al., 2011; Hayashi and Surani, 2009).
However, the majority of EpiSCs functionally display features of
late-stage postimplantation epiblasts.
Using a pteridine-derived inhibitor, which we discovered previ-
ously (Ursu et al., 2016), we here show that inhibition of casein ki-
nase 1alpha (CK1alpha) can promote the efficient conversion of
recalcitrant EpiSCs into ESC-like cells. Furthermore, we demon-
strate that the conversion ismediated by the combined activation
of WNT signaling and attenuation of transforming growth factor
beta (TGFbeta) signaling, resulting in the activation of the ESC
pluripotency gene regulatory network. These findings provide
mechanistic insights into themolecular switch governing the tran-
sition between distinct pluripotent states.
RESULTS
Triamterene Induces Conversion of Late-Stage EpiSCs
Two Oct4 reporter lines (GOF18, which harbors all known
Oct4 regulatory elements, and OG2, which lacks the proximal
enhancer; PE) were used to study the different states of pluripo-
tency (Yeom et al., 1996) (Figure 1A). ESCs of both reporter lines
express GFP when cultured under ESC culture conditions
(Bernemann et al., 2011; Han et al., 2010). The corresponding
EpiSCs, when cultured under EpiSC conditions, do not expressFigure 1. TR Induces ESC Conversion of Recalcitrant EpiSCs
(A) Oct4-GFP expression after treatment with 2i/LIF (top) and TR (5 mM; bottom) fo
measured by flow cytometry (FSC, forward scatter). The basal medium for the co
and, for the conversion with TR, EpiSC conditioned medium containing FGF2 an
(B) Comparison of gene expression patterns in ESCs, TR-GOF18 cells, and EpiS
data represent mean ± SD of triplicates; n = 3).
(C) Scatterplot of global gene expression microarrays comparing TR-GOF18 ce
unsorted E3 EpiSCs and ESCs (top) is shown as control. The black lines delinea
expressed in TR-GOF18 cell samples compared with ESC samples are shown as
pluripotent cell marker Zfp42/Rex1 and the germ cell markerDppa3/Stella are indi
the higher the scattering density, the darker the blue. The gene expression level
(D) Immunofluorescence analysis for Klf4 and Esrrb proteins in recalcitrant EpiSC l
bar represents 200 mm).
(E) X chromosome reactivation and immunofluorescence analysis for Esrrb pro
represents 200 mm).
See also Figure S1.GFP, except for a small subpopulation previously shown to
contribute to the formation of chimeras (Han et al., 2010). Both
Oct4-GFP-negative GOF18 EpiSCs and OG2 EpiSCs were
found to be recalcitrant to 2i/LIF-based ESC conversion, which
is consistent with findings of previous reports (Bernemann
et al., 2011; Han et al., 2010) (Figure 1A, upper).
In our initial screen, triamterene (TR) was identified using un-
sorted GOF18 EpiSCs. Here, we tested the effect of TR on the
recalcitrant Oct4-GFP-negative fraction of the GOF18 EpiSC
line, the EpiSC line OG2 (Figure 1), and the extremely recalcitrant
cell lines T9 and C1a1 (Bernemann et al., 2011) (Figure S1). After
culturing the Oct4-GFP-negative fraction with TR for 7 days,
more than 30%were found to become GFP positive, even under
EpiSC culture conditions (Figure 1A, bottom left). Similar results
were obtained with the EpiSC line OG2 (Figure 1A, bottom right).
In contrast, applying stringent mESC conditions alone (2i/LIF)
failed to revert the different late-stage EpiSCs to a putative naive
state (Figure 1A, upper).
Clonal lines from the TR-reverted GOF18 ESC-like cells
(TR-GOF18) expressed ESC-specific markers, such as Rex1,
Stella, Klf2, Klf4, and Esrrb (Figure 1B). In contrast, the expres-
sion of genes typically expressed in EpiSCs, such as T-bra-
chyury, Fgf5, and Fgf8, was reduced in TR-induced cells.
Most importantly, global gene expression analysis showed
obvious assimilation of the gene expression profiles of TR-con-
verted cells and ESCs (Figure 1C, middle; see also Figures 3A
and S3B).
We then assessed the ability of TR to convert EpiSC lines (T9
and C1a1), which are especially resistant to media-induced con-
version using 2i/LIF (Bernemann et al., 2011). We found that TR
efficiently induces the reactivation of ESRRB and KLF4 proteins
in T9 and C1a1 EpiSCs and promotes a change in colony
morphology to small dome-shaped colonies (Figure 1D). The
relative conversion efficiency of TR for these cell lines was
measured based on the expression of the pluripotency marker
PECAM1/CD31 (Figure S1A). After treatment with TR, the T9
and C1a1 cell lines expressed PECAM1 at significantly lower
levels than the other two cell lines (Figure S1A). The lower con-
version rates of the T9 and C1a1 EpiSCs may partly be due to
spontaneous differentiation even under EpiSC culture conditions
(see differentiated areas in Figures 1D, S1B, and S3B for early
differentiation markers, such as Fgf5 and Fgf8).r 7 days in sorted Oct4-GFP-negative GOF18 EpiSCs (left) and OG2 EpiSCs as
nversion with 2i/LIF was ESC medium (20% serum replacement in KO-DMEM)
d Activin A.
Cs. The expression levels are normalized to those of unsorted E3 EpiSCs (the
lls with ESCs (middle) and unsorted E3 EpiSCs (bottom). The comparison of
te the boundaries of 4-fold difference in gene expression levels. Genes highly
red dots; those less expressed are shown as green dots. The positions of the
cated as orange dots. The color bar to the right indicates the scattering density;
s are depicted on log2 scale.
ines C1a1 (top) and T9 (bottom) following treatment with TR for 7 days (the scale
tein in female EpiSCs following treatment with TR for 7 days (the scale bar
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The effectiveness of TR in reinstating ESC pluripotency in
EpiSCs was further tested using an X-Chromosome-GFP re-
porter in female EpiSCs (Hadjantonakis et al., 1998). This
reporter had been previously shown to faithfully discriminate
between ESCs and EpiSC-like cells, as this transgene specif-
ically becomes reactivated in the naive state (Han et al., 2011).
Thederivationof X-GFPEpiSCshasbeenpreviously described
(Gillich et al., 2012). Hence, an induction of ESC pluripotency
should lead to X chromosome reactivation, and, conversely, the
expression of X-GFP would be indicative of a successful rever-
sion of these cells. Culturing these EpiSCs in TR-containing
media changed the morphology of these cells toward that of
ESC-like colonies and, indeed, successfully promoted the reac-
tivation of X-Chr-GFP and expression of ESRRB protein in these
cells (Figure 1E).
During the conversion of GOF18 or OG2 EpiSCs with TR, the
first dome-shaped Oct4-GFP-positive colonies appeared after
4 days. It was unclear whether TR was required throughout the
whole culture period or whether a shorter exposure of TR would
enable EpiSCs to convert under 2i/LIF conditions. To address
this, sorted Oct4-GFP-negative E3 EpiSCs were treated with TR
under EpiSC conditions for varying time periods, followed by
further culturing under the 2i/LIF condition (FigureS1C).We found
that pretreatment with TR even for 3 days followed by 2i/LIF did
not produce any GFP-positive colonies. On the fourth day of TR
treatment, the first Oct4-GFP-positive colonies appeared. How-
ever, even after 4 days, 2i/LIF did not have any effect on the num-
berof colonies, as themedium lackingbothTRand2i/LIF gave the
same number of colonies. We therefore concluded that TR had
to be present for 6 days in order for EpiSCs to undergo efficient
conversion to an ESC-like state (Figure S1C).
Taken together, the presence of TR during a period of 6 days
induced the efficient conversion of late-stage EpiSCs toward a
cellular state that is similar to that of ESCs.
PD0325901 Stabilizes the TR-Induced Transition to ESC
Pluripotency
Although TR-converted cells and ESCs are quite similar, even
clonal populations of E3 ESC-like cells always contained some
Oct4-GFP-negative cells, which were not observed in ESCs
cultured in KO-DMEM/KOSR (KO serum replacement)/LIF. We
took this as an indication that TR on did not fully establish,
and/or did not sufficiently maintain, ESC pluripotency (Figure 2A;
compare left and middle). Analyses of gene expression and pro-
moter methylation of ICM marker genes in these two TR-GOF18
populations showed that the Oct4-GFP-positive cell population
more closely resembled ESC-like features than the Oct4-GFP-
negative population. In fact, the latter cell fraction was more
similar to EpiSCs (Figures S2A and S2B).
To achieve homogeneous and complete conversion of EpiSCs
into ESC-like cells, we treated the TR-converted cells with a
selected set of chemical inhibitors known to support ESC self-
renewal, as well as with a collection of compounds synthesized
in-house (Nie et al., 2012). We found that culturing the TR-con-
verted cells in KO-DMEM/KOSR/LIF together with the MEK
inhibitor PD0325901 (PD) dramatically increased theproportion of
Oct4-GFP-positive cells after only 48 hr (Figure 2A; compare
middle and right). TR/PD-converted cells and ESCs were790 Cell Reports 15, 787–800, April 26, 2016indistinguishable with respect to cell morphology, growth char-
acteristics, alkaline phosphatase (AP) activity, and Oct4-GFP
expression (Figure S2C). At the molecular level, ESC-specific
markers were (re-)expressed, while EpiSCmarkers were reduced
in TR/PD-converted cells (Figure 2B). In contrast to EpiSCs,
colonies of TR/PD-converted cells exhibited homogeneously ex-
pressedprotein levels of SOX2,NANOG, andSTELLA (Figure 2C).
ESCs preferentially use the distal enhancer (DE) to drive Oct4
expression, while EpiSCs use the PE (Tesar et al., 2007; Yeom
et al., 1996). Using a luciferase assay, we compared the activity
of the Oct4 enhancer in the reverted cells with that of ESCs and
EpiSCs. The PE/DE ratio in TR/PD-reverted cells was tilted to-
ward the preferential use of the Oct4 DE, like ESCs but unlike
EpiSCs (Figure 2D). In accordance, TR/PD cells exhibited a
global gene expression pattern that closely resembled that of
ESCs (Figure 2E; see also Figures 3A and S3B).
We next assessed the responsiveness of the TR/PD-reverted
cells toESC- andEpiSC-related signaling pathways (FigureS2D).
In order to propagate, EpiSCs depend on TGFbeta/SMAD2/3
signaling, whereas ESCs require stimulation of the LIF/STAT3
pathway. Inhibition of LIF/STAT3 signaling in ESCs was found
to induce differentiation, i.e., pluripotency markers were down-
regulated and early differentiation markers were upregulated,
compared with the untreated control (Figure S2D, left; see
ESC+JAKi). In contrast, inhibition of TGFbeta/SMAD2/3 signaling
in EpiSCs induced differentiation (Figure S2D, right; see
EpiSC+SB). Upon inhibition of these two pathways, TR/PD cells
reacted, in both cases, similarly to ESCs and differently from
EpiSCs, indicating a switch in the signaling pathways toward
those related to ESC pluripotency (Figure S2D; see TR/PD+JAKi
in left and TR/PD+SB in right). Notably, in both cases, TR-con-
verted cells showed a more moderate response than ESCs and
TR/PD-converted cells, again suggesting that TR alone primes
EpiSCs for a complete switch of cell states (Figure S2D; see
TR-GOF18+JAKi in left and TR-GOF18+SB in right).
Germline Competence Is Restored in TR/PD-Converted
Cells
The converted cells were compared to EpiSCs and ESCs by
global gene expression analysis. The heatmaps of TR/PD cells
were found to be very similar to those of ESCs (Figure 3A), which
was also confirmed by hierarchical clustering analysis (Fig-
ure S3A). The most differentially expressed genes between
TR-converted and TR/PD cells give insight into the specific ge-
netic changes that distinguish the two cell types (Figure S3B).
For example, the ICM markers Dppa5, Esrrb, Dppa4, Klf2, and
Nr5a2 were expressed in TR-GOF18 cells at levels comparable
to those in ESCs. Other ICM markers, such as Tcl1, Tbx3, and
Klf4, were also strongly induced in TR-GOF18 cells compared
with EpiSCs but reached the expression levels of ESCs only
upon inhibition of the MEK pathway (addition of PD). MEK
inhibition also resulted in the suppression of early differentiation
markers, such as Fgf5 and Fgf8, which were elevated in
TR-GOF18 cells (or a subset thereof).
We then assessed whether the aforementioned switch in
gene expression was accompanied by a global change in the
methylation state of TR/PD-converted cells. Consistent with
the gene expression data (Figures 1B and 2B), the endogenous
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Figure 2. MEK Inhibition in TR-Treated Recalcitrant EpiSCs Improves the Transition to ESC Pluripotency
(A) Percentage of Oct4-GFP-positive cells in ESCs, TR-GOF18 cells, and TR/PD cells as measured by flow cytometry (forward scatter: FSC). TR-GOF18 rep-
resents a clonal cell line of TR-converted E3 EpiSCs, which was maintained under ESC culture conditions for more than 30 passages. The TR/PD represents a
clonal cell line of TR-GOF18 cells after treatment with theMEK inhibitor PD (1 mM) for 2 days. The TR/PD cells weremaintained under ESC culture conditions in the
presence of PD.
(B) Comparison of gene expression patterns in ESCs, TR-GOF18 cells, and TR/PD cells. The expression levels are normalized to those of unsorted E3 EpiSCs (the
data represent mean ± SD of triplicates; n = 3).
(C) Immunofluorescence analysis for Sox2, Nanog, and Stella (Dppa3) in ESCs, TR-GOF18 cells, EpiSCs, and TR/PD-converted cells. DAPI was used for nuclear
staining (the scale bar represents 350 mm).
(D) Luciferase assay showing the ratios of Oct4 enhancer activity in ESCs, TR-GOF18 cells, EpiSCs, and TR/PD-converted cells. The enhancer activities in
EpiSCs and TR-GOF18 cells are normalized to the DE activity, which is set to 1. The enhancer activities in ESCs and TR/PD cells are normalized to the PE activity,
which is set to 1. The relative luciferase activities were also normalized to the activity of an empty vector (the data represent mean ± SD of triplicates; n = 3; and
p < 0.001).
(E) Scatterplot of global gene expression microarrays comparing TR/PD cells with ESCs. For control scatterplots, see Figure 1C. The black lines delineate the
boundaries of 4-fold difference in gene expression levels. The genes highly expressed in TR/PD samples compared with ESC samples are shown as red dots;
those less expressed are shown as green dots. The positions of the pluripotent cell marker Zfp42/Rex1 and the germ cell marker Dppa3/Stella are indicated as
orange dots. The color bar to the right indicates the scattering density; the higher the scattering density, the darker the blue color. The gene expression levels are
depicted on log2 scale.
See also Figure S2.Oct4 promoter was found to be completely unmethylated in both
ESCs and EpiSCs, while the Oct4-GFP transgene promoter was
mainly unmethylated in ESCs and highly methylated in EpiSCs(Figure 3B). In TR/PD cells, the Oct4-GFP transgene promoter
was basically unmethylated, whereas in TR-converted cells,
the transgene promoter was only partially unmethylated.Cell Reports 15, 787–800, April 26, 2016 791
Figure 3. Combined Treatment with a MEK
Inhibitor and TR Restores Germline Compe-
tency in EpiSCs
(A) Heatmap of global gene expression patterns in
ESCs, TR-GOF18 cells, unsorted E3 EpiSCs, and
TR/PD cells. The color bar at the top codifies the
gene expression in log2 scale. The red and blue
colors indicate high and low gene expression
levels, respectively.
(B) DNAmethylation status of the promoter regions
of ICM marker genes in ESCs, TR-GOF18 cells,
unsorted E3 EpiSCs, and TR/PD cells was
analyzed using bisulfite-sequencing PCR.
(C) Representative image of a teratoma derived
from TR/PD cells in a teratocarcinoma assay,
together with representative tissues of ectodermal
(skin epithelium), mesodermal (muscle), and endo-
dermal (gut-like) lineages in teratomas obtained
from TR/PD cells (the scale bar represents 50 mm).
(D) Embryonic and germline contribution of TR/PD
cells. The blastocyst injection using TR/PD cells
was performed, and the contribution of the cells to
the ICM (left; the scale bar represents 50 mm),
midterm (E14.5) pups (middle), and germline (right;
the scale bar represents 450 mm) was assessed.
See also Figure S3.Demethylation was also observed for other marker genes
analyzed in TR/PD-converted cells (Figure 3B).
Following global gene expression and methylation analysis,
we sought to functionally characterize the reverted cells using
in vivo differentiation assays. TR/PD-converted cells were
found to give rise to teratomas containing tissues of all germ
layers (Figure 3C). Most importantly, upon injection into blasto-
cysts, TR/PD-converted cells showed successful integration
into the ICM and, consequently, contribution to the germline
(Figure 3D).
The TRDerivative Epiblastin A Is aPotent Inducer of ESC
Pluripotency in EpiSCs
Kinase profiling and subsequent gene knockdown (KD) ex-
periments had revealed that CK1alpha is a target enzyme in
TR-induced ESC conversion, and structure-activity relationship
analyses with chemically synthesized derivatives of TR yielded792 Cell Reports 15, 787–800, April 26, 2016Epiblastin A as the most potent TR-
derived CK1 inhibitor (Ursu et al., 2016).
Next, the ability of Epiblastin A to pro-
mote the reversion of EpiSCs was
analyzed in further detail. Among the set
of compounds examined, Epiblastin A
was found to exhibit the highest con-
version efficiency based on Oct4-GFP
and PECAM1 reactivation, almost 2-fold
higher thanTR (Figure 4A).CHandsodium
butyrate had a negligible effect on the
reactivation of Oct4-GFP and PECAM1
(Figure 4A). This is a compelling finding,
as Epiblastin-A-converted cells exhibited
similar cell morphology; Oct4-GFP ex-pression; AP immunoreactivity; protein levels of SOX2, NANOG,
and STELLA; and gene expression profiles as ESCs (Figures 4B–
4D). Most importantly, Epiblastin A/PD-converted cells regained
the ability to contribute to chimera development when injected
into blastocysts (Figure 4E).
CK1 Inhibition Promotes the Activation/Maintenance of
the ESC Pluripotency Gene Regulatory Network
The next question was how the inhibition of CK1 influenced the
expression of known pluripotency factors. To address this
point, EpiSCs were treated with TR for 2, 4, 6, and 8 days.
Notably, the expression of Klf2, Nanog, and Esrrb was upregu-
lated from day 2 onward, albeit with different dynamics (Fig-
ure 5A). After 8 days of treatment with TR, expression levels
of Nanog and Esrrb even exceeded those in ESCs. This result
was recapitulated using D4476, an independent inhibitor of
CK1 (Figure S4A).
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Next, the role of Klf2, Nanog, and Esrrb during Epiblastin-
A-based conversion was determined by small hairpin RNA
(shRNA)-based KD experiments (Figures 5B and S4B). Nanog
KD, by far, had the strongest effect, as it essentially abolished
reversion by Epiblastin A. Klf2 KD also significantly reduced
reversion efficiencies, suggesting critical roles for both Nanog
and Klf2 in the process of reprogramming. Esrrb KD had a less
dramatic effect, reducing the action of Epiblastin A by about
30% (Figure 5B).
As CK1 inhibitors have an impact on key pluripotency genes
during the reversion of EpiSCs into ESC-like cells, we sought
to test whether Epiblastin A and TR can affect self-renewal
based on their ability to maintain the pluripotency gene regula-
tory network. High levels (5 mM and above) of Epiblastin A or
TR were found to be toxic (data not shown), and N2B27 me-
dium alone was not permissive for ESC self-renewal. However,
following a titration experiment, an optimal working concentra-
tion of 2 mMEpiblastin A was found to promote clonal expansion
of ESCs in N2B27. Addition of either LIF or PD to Epiblastin-A-
supplemented media increased the cells’ ability to self-renew,
whereas addition of CH to Epiblastin-A-supplemented media
decreased their ability (Figure 5D).
Upon switching to EpiSC media (based on N2B27/Activin
A/bFGF), ESCs acquire properties of primed pluripotency (Guo
et al., 2009). Nanog-GFP ESCs show progressive downregula-
tion of Nanog-GFP under this condition (Chambers et al., 2007;
Karwacki-Neisius et al., 2013). WNT signaling has been reported
to prevent the commitment of ESCs into EpiSCs (ten Berge et al.,
2011). Consistent with this observation, we found that downre-
gulation of Nanog-GFP during EpiSC differentiation was blocked
by the addition of TR, with an efficacy comparable to that of the
WNT agonist CH (Figure 5C). On the other hand, ESCs cultured in
the presence of serum and LIF are known to exhibit transcription
factor heterogeneity, coinciding with the presence of cells with
different self-renewal abilities (Chambers et al., 2007). To test
the ability of TR to maintain the homogeneous expression of
ICM transcription factors, we used the two reporter lines
Nanog-GFP and Esrrb-Tomato. TR treatment induced a high
and homogeneous expression of Nanog-GFP and Esrrb-Tomato
for the duration of the assay, whereas untreated controls gave
rise to Nanog-GFP-negative and Esrrb-Tomato-negative cells
(Figure S4C).
Inhibition of CK1alpha Results in Simultaneous
Activation of WNT Signaling and Inhibition of TGFbeta/
SMAD2 Signaling
We next turned our attention to themechanism underlying the in-
hibition of CK1. Signaling pathways known to be involved in ESCFigure 4. The TR Derivative Epiblastin A Is a Potent Inducer of ESC Plu
(A) Percentage of Oct4-GFP and PECAM1 (CD31) double-positive cells after 7 d
CH: 3 mM), CH (3 mM), NaB (100 mM), and D4476 (20 mM) in unsorted GOF18 Ep
(B) Morphology, Oct4-GFP, and ALP expression in Epiblastin A-GOF18 cells (lef
(C) Immunofluorescence analysis for Sox2, Nanog, and Stella (Dppa3) in Epibla
represents 300 mm).
(D) Comparison of gene expression patterns in ESCs, Epiblastin A-GOF18 cells, a
represent mean ± SD of triplicates; n = 3).
(E) Chimeric mice derived from Epiblastin A-GOF18 cells after blastocyst injectio
794 Cell Reports 15, 787–800, April 26, 2016pluripotency were analyzed by using CK1 inhibitors. We found
that Epiblastin A prevented phosphorylation of BCATENIN and
SMAD2 (Figure 6A). It also affected STAT3 phosphorylation,
probably due to inhibition of PI3K, as identified by kinase
profiling. In contrast, ERK (and, consequently, probably the
entire ERK pathway) was not affected (Figure 6A).
Following the inhibition of phosphorylation of BCATENIN, we
further analyzed the effect of Epiblastin A and TR on the WNT
pathway. To determine the enrichment of factors associated
with signaling pathways, a Gene Ontology enrichment analysis
was performed with the genes that were significantly upregu-
lated within 12 hr of treatment of EpiSCs with TR. Based on
this analysis, the WNT receptor signaling pathway clearly ranked
at the top of significantly enriched ‘‘biological process’’ terms
(Figure S5A). The known WNT/TCF (T-cell-factor) target genes
Axin2, Cdx1, and T-brachyury were upregulated upon TR treat-
ment (Figure S5B) (Kelly et al., 2011). We then performed the
TOPFlash TCF-Luciferase assay to assess the WNT-inducing
activity of Epiblastin A and found that Epiblastin A was more
active than CH (Figure 6B).
Then we tested whether the positive effect of Epiblastin
A treatment on ESC self-renewal was dependent on the
WNT/BCATENIN pathway (Figure 5D). To this end, we used
an ESC line in which both BCATENIN alleles had been floxed
and that carried a CreERT2 cassette inserted into the ROSA26
locus (BCATENINfl/fl) (Brault et al., 2001; Tsakiridis et al.,
2014). Treatment of BCATENINfl/fl ESCs with 4-hydroxytamoxi-
fen induced the deletion of both BCATENIN alleles, generating
BCATENIN/ ESCs (Figure 6D, western blot). BCATENIN/
ESCs were unable to self-renew in the presence of CH/PD (2i)
or CH/LIF (Figure 6D, right). The combined presence of only
PD and LIF supports self-renewal in the absence of BCATENIN,
albeit with decreased efficiency (Wray et al., 2011). Interestingly,
although self-renewal efficiency was equally diminished by the
depletion of BCATENIN, Epiblastin Awas still capable of sustain-
ing the ESC state (Figure 6D, right).
Finally, we assessed the potential of Epiblastin A and TR to
modulate the WNT pathway in vivo. Zebrafish embryos 7–48 hr
postfertilization (hpf) were kept in the presence of Epiblastin A
or TR. At 48 hpf, zebrafish embryos exhibited a phenotype char-
acteristic of WNT overactivation during this period of develop-
ment, including impaired development of the eyes, forehead,
and tail (Figure 6C).
P-SMAD2wasaffectedbybothEpiblastinAandTR (Figure6A).
Therefore, we determined the role of SMAD2 during the reversion
process. We hypothesized that Epiblastin A and TR might act by
inhibiting the phosphorylation of both BCATENIN and SMAD2;
therefore, we simulated this action by using CH together withripotency in EpiSCs
ays of ESC conversion with Epiblastin A (5 mM), TR (5 mM), 2i (PD: 1 mM and
iSCs as measured by flow cytometry.
t; the scale bars represent 300 mm).
stin A-GOF18 cells. DAPI was used for nuclear staining (right; the scale bar
nd EpiSCs. The expression levels are normalized to those of EpiSCs (the data
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Figure 5. Casein Kinase 1 Inhibition Promotes the Activation/Maintenance of the ESC Pluripotency Gene Network
(A) Time-course analysis for whole mRNA expression of Klf2, Nanog, and Esrrb in TR-treated EpiSCs. The gene expression levels are normalized to those of
untreated EpiSC samples (the data represent mean ± SD of triplicates; n = 3).
(B) Percentage of Oct4-GFP and PECAM1 (CD31) double-positive cells after 6 days treatment with Epiblastin A, together with shRNA-based KD of Esrrb,Nanog,
and Klf2, respectively, in GOF18 EpiSCs as measured by flow cytometry.
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SB431542 (SB), an inhibitor of TGFbeta/SMAD2/3 signaling.
Interestingly, while CH or SB promoted the differentiation of
EpiSCs, when combined, they gave rise to ESC-like colonies ex-
pressing Oct4-GFP and ICMmarker genes at levels comparable
to those of ESCs (Figures 6E and 6F). Just likewith Epiblastin A or
TR, the conversion with CH/SB took 4–6 days and could even be
achieved under EpiSC culture conditions.
A role for different CK1 isoenzymes in BCATENIN and
SMAD2 phosphorylation had been reported by earlier studies
(Amit et al., 2002; Waddell et al., 2004). We had previously
found that KD of CK1alpha gave rise to a significant percentage
of Oct4-GFP-positive cells compared with KD of either CK1ep-
silon or CK1delta. To determine whether a particular CK1
isoenzyme is involved in BCATENIN and SMAD2 phosphoryla-
tion, we performed an shRNA (short-hairpin-RNA)-based KD of
CK1alpha, CK1delta, and CK1epsilon in EpiSCs (Figure S5C).
Western blot analysis revealed that KD of either CK1alpha or
CK1epsilon affected the phosphorylation of both BCATENIN
and SMAD2 (Figure S5D). As TR did not inhibit GSK3beta
and ALK (Ursu et al., 2016), these findings suggest that
Epiblastin A and TR act on BCATENIN and SMAD2 phos-
phorylation via CK1alpha and CK1epsilon. Having obtained a
significant population of Oct4-GFP-positive cells after KD of
CK1alpha in E3 EpiSCs, we then derived and stably maintained
a clonal cell line from this population. These cells strongly
resembled ESCs in morphology, growth behavior, and Oct4-
GFP expression. Global gene expression profiling revealed a
gene expression pattern indistinguishable from that of ESCs
(Figure S5E).
Finally, we sought to clarify the role played by LIF in the rever-
sion process. TR was found to inhibit PI3K, which may explain
the blocked STAT3 phosphorylation, pointing toward a redun-
dancy of this pathway during conversion (Figure 6A). Moreover,
ESCs could be maintained with Epiblastin A alone, i.e., without
LIF (Figure 5D), and SB/CH could equally maintain ESCs
without LIF (data not shown). To categorically determine whether
LIF/STAT3 signaling is involved in Epiblastin-A-mediated self-
renewal, we used Stat3/ ESCs. These ESCs require CH/PD
(2i) supplementation for propagation (Ying et al., 2008). In
the absence of Stat3, Epiblastin-A-mediated self-renewal was
severely reduced in the presence of either LIF or CH (Figure S5F).
In contrast, the dual inhibition of ERK and CK1 (N2B27/PD/Epi-
blastin A) promoted the robust propagation of Stat3/ ESCs,
for more than 2 months (Figure S5F). Stat3/ ESCs cultured
for more than 2 months in PD/Epiblastin A were found to retain
robust expression of OCT4, NANOG, ESRRB, and KLF4 proteins
and to give rise to chimeric mice after blastocyst injection (Fig-
ures S5G and S5H). Taken together, our data suggest a concise
mechanism of action for Epiblastin A and TR that is based on
BCATENIN and SMAD2 modulation via inhibition of CK1alpha
(Figure 6G).(C) Differentiation of ESCs into EpiSCs is blocked by supplementation with TR.
entiation (A/F) and in the presence of either Chiron or TR is shown (A, Activin
Puromycin selects for the expression of Nanog. The selection cassettes are part
(D) Clonal assay of ESCs in the indicated culture conditions. The ESCs were plate
stained for AP and counted (L, LIF; E, Epiblastin A).
See also Figure S4.
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As previously shown, EpiSCs are heterogeneous within and
among cell lines (Bernemann et al., 2011; Han et al., 2010; Tsa-
kiridis et al., 2014; Bao et al., 2009). Only a small subpopulation
of EpiSCs displays features of the early postimplantation
epiblast (Bao et al., 2009; Han et al., 2010), whereas the vast
majority of EpiSCs functionally represent cells of late-stage post-
implantation epiblast. Early-stage EpiSCs are susceptible to me-
dia-induced reversion into cells of an ESC-like state, whereas
late-stage EpiSCs are refractory to this process (Figure 1A) (Ber-
nemann et al., 2011; Han et al., 2010). In this study, we show that
a small molecule compound, which was previously discovered
in our laboratory, is capable of inducing the reversion of both
early- and late-stage EpiSCs into ESC-like cells, and we herein
describe its underlying mechanism of action. To our knowledge,
this is the first study showing the robust conversion of late-stage
EpiSCs into ESCs through chemical means only.
The conversion of EpiSCs into ESC-like cells by Epiblastin
A and TRdisplays several striking features. After a relatively short
exposure period to induce ESC pluripotency (6–8 days), cells
converted by Epiblastin A or TR could be clonally expanded
and maintained in LIF-supplemented ESC medium, without
needing to further add either inhibitor. Notably, we found that
TR induces the expression of Oct4-GFP in EpiSC medium in
the absence of exogenous LIF. This likely occurs due to the pres-
ence of LIF in MEF (mouse embryonic fibroblast)-conditioned
medium. However, Epiblastin A and TRwere also found to inhibit
PI3K-mediated STAT3 phosphorylation, indicating a redun-
dancy of this pathway during the conversion process (Figure 6A).
Activation of the FGF/ERK pathway predisposes ESCs to dif-
ferentiation (Greber et al., 2010; Kunath et al., 2007). Conversely,
ERK inhibition, in combination with LIF and/or CH, supports the
maintenance of undifferentiated ESCs (Ying et al., 2008). This is
consistent with our observation that ERK inhibition in TR-con-
verted cells finalizes and/or stabilizes the transition of these cells
to ESC pluripotency (Figures 2 and 3).
Several kinase inhibitors have been reported either to support
the generation of induced pluripotent stem (iPS) cells or to
promote the conversion to ESC-like pluripotency (Ying et al.,
2008; Li and Rana, 2012; Sato et al., 2004; Ichida et al., 2009;
Maherali and Hochedlinger, 2009). Notably, TR did not inhibit
GSK3beta, MEK/ERK, or ALK4/5, which are all targets of inhibi-
tors that promote the reversion of EpiSCs into ESC-like cells
(Greber et al., 2010; Zhou et al., 2010). This observation sug-
gested that TR must be working through the regulation of a
different kinase.
Kinase profiling revealed that Epiblastin A and TR inhibited
CK1 isoenzymes, and KD of CK1alpha gave rise to Oct4-GFP-
positive colonies; inhibiting either CK1epsilon or CK1delta had
no effect at all. These cells had a gene expression profile thatThe flow-cytometry analysis of Nanog-GFP-positive cells during EpiSC differ-
A; F, bFGF). Black cell population represents non-fluorescent control cells).
of the reporter construct that was knocked in into the Nanog locus.
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was indistinguishable from that of ESCs, and KD of CK1alpha re-
sulted in reduced BCATENIN and SMAD2 phosphorylation, thus
further substantiating a role for CK1alpha in the reprogramming
process (Figures S5C and S5D).
CK1 family members are known to exert both negative and
positive effects onWNT signaling (Price, 2006). Potential contact
points for negative WNT regulation via CK1-mediated phosphor-
ylation include BCATENIN (Amit et al., 2002; Liu et al., 2002), APC
(Rubinfeld et al., 2001), and LRP5/6 (Swiatek et al., 2006). How-
ever, members of the CK1 family are also known to be involved
in numerous other processes, including p53 and E-cadherin
modifications, nuclear-cytoplasmic shuttling of transcription fac-
tors, and TGFbeta signaling (Rena et al., 2004; Waddell et al.,
2004; Knippschild et al., 1997; Dupre-Crochet et al., 2007). It is
also known that TR inhibits dihydrofolate reductase, acting as
an antifolate due to the common pteridine structure of these
two proteins (Corcino et al., 1970; Schalhorn et al., 1981). The
resulting inhibition of DNA synthesis could explain the toxicity
of Epiblastin A and TR when used in higher concentrations.
We confirmed the agonistic effect of Epiblastin A and TR on
the WNT pathway both in vitro and in vivo. Furthermore, we
showed that both Epiblastin A and TR simultaneously modulate
WNT/BCATENIN and TGFbeta/SMAD2 signaling by inhibiting
CK1alpha. Accordingly, we could also demonstrate that simulta-
neous activation of the WNT pathway and inhibition of SMAD2
signaling can mimic the Epiblastin-A- or TR-based reprogram-
ming mechanism, in contrast to perturbing the two pathways
individually (Figures 6 and S5). That is why neither SB nor CH
could convert EpiSCs to ESC pluripotency.
Treatment of EpiSCs with TR coincided with strong upregula-
tion of the key ESC-specific pluripotency markers Klf2, Nanog,
and Esrrb (Figure 5A). Interestingly, KD of Klf2 or Nanog signifi-
cantly impaired Epiblastin-A/TR-based EpiSC reversion, high-
lighting the importance of these factors during this process
(Figure 5B). KD of Esrrb reduced the number of Epiblastin-A-
induced Oct4-GFP-positive cells by half (Figure 5B). However,
shRNA probes for Esrrb were less efficient than those for Nanog
and Klf2 (Figure S4B). These intrinsic factors may be important
for the chemical-induced reversion of EpiSCs, consistent with
previous reports that they are efficient in promoting conversionFigure 6. Epiblastin A/TR Treatment Simultaneously Activates WNT Si
(A) Western blot analysis showing the effects of Epiblastin A and Chiron on BCA
treated with either Epiblastin A or Chiron for 30 min. An additional experiment
p-BCATENIN of the applied antibody (lower band indicated with an arrow).
(B) Luciferase assay of TCF/Lef-mediated transcriptional activity in EpiSCs as a r
control. The columns depict the TOP/FOP ratio (the data represent mean ± SD o
(C) Phenotypes of zebrafish embryos at 48 hpf. The embryos were allowed to grow
500 mm).
(D) Clonal assay of Bcateninfl/fl and Bcatenin/ ESCs in the indicated culture con
coated plates and cultured for 7 days, after which, the cells were stained for AP
earlier. After 48 hr, the cells were treated with 1 mM of 4-hydroxytamoxifen for 2
demonstrates successful excision of Bcatenin after treatment with 4-hydroxytam
(E) Morphology and Oct4-GFP expression in sorted Oct4-GFP-negative E3 EpiS
scale bar represents 200 mm).
(F) Real-time qPCR analysis of ICM marker gene expression in SB/CH-treated ce
unsorted E3 EpiSC samples (the data represent mean ± SD of triplicates; n = 3).
(G) Schematic model of the mechanism by which TR/Epiblastin A reverts recalci
See also Figure S5.
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2009; Hall et al., 2009).
Taken together, our results demonstrate not only that ESC plu-
ripotency can be induced in late-stage EpiSCs, but also that this
conversion can bemade simple and very efficient. Moreover, our
findings reveal insights into the mechanisms governing the tran-
sition between distinct states of pluripotency. This is of special
interest, as we describe the conversion of the two extremes of
pluripotency that have been defined to date. Notably, we intro-
duce CK1alpha as a key player in the regulation of ESC pluripo-
tency, through the direct modulation of WNT/BCATENIN and
TGFbeta/SMAD2 signaling. These findings open the door to
addressing numerous questions. For example, we can now
determine whether the role of CK1 in the regulation of ESC plu-
ripotency is conserved across species. Additionally, by means
of CK1 inhibition and appropriate culture conditions, we now
can define a pluripotent state that corresponds to day 3.5 ICMs.
EXPERIMENTAL PROCEDURES
Cell Culture
The derivation of EpiSC lines is described elsewhere (Greber et al., 2010).
EpiSCs were cultured on feeder-free dishes that had been precoated with fetal
calf serum (FCS) for 15 min in MEF (CF1 mice)-conditioned medium. EpiSC
medium before MEF conditioning consisted of DMEM/F12 (Gibco BRL) con-
taining 20% knockout (KO) serum replacement (Gibco BRL), 2 mM glutamine,
13 nonessential amino acids, and 5 ng/ml bFGF. For conditioning, irradiated
MEFs were seeded at a density of 5 3 104 cells per square centimeter and
incubated in EpiSC medium for 24 hr. The conditioned medium was filtered,
and bFGF (5 ng/ml) was added (this was termed CM/FGF). EpiSCs were
passaged using Accutase (Invitrogen) and seeded as single cells at approxi-
mately 15,000 cells per 6-cm dish. Medium was changed every 24 hr. ESCs,
TR-GOF18, and TR/PD-converted cells were cultured on irradiated MEFs
or on gelatin-coated plates in KO-DMEM medium containing 20% KO serum
replacement, 2 mM glutamine, 13 nonessential amino acids, and LIF
(1,000 U/ml). ESCs, TR-GOF18, and TR/PD-converted cells were passaged
using trypsin (Invitrogen).
ESC Conversion of EpiSCs
EpiSCs were dissociated using Accutase and plated as single cells either on
g-irradiated MEF feeder cells or on FCS-coated tissue culture plates at low
density (%10,000 cells per well of a six-well plate) and cultured overnight in
MEF-conditioned EpiSC medium supplemented with bFGF. Depending ongnaling and Inhibits TGFbeta/SMAD2 Signaling
TENIN, SMAD2, STAT3, and ERK phosphorylation in EpiSCs. The cells were
was performed using a BCATENIN KO cell line to prove specific binding to
esult of Epiblastin A and Chiron treatment. The Chiron was used as a positive
f triplicates; n = 3; and p < 0.001).
in the presence of the indicated inhibitors from 7 hpf (the scale bar represents
ditions. Bcateninfl/fl ESCs were plated at clonal density (600 cells) onto gelatin-
and counted. To generate Bcatenin/, Bcateninfl/fl were plated as described
4 hr to induce the Cre excision of the floxed-Bcatenin. Western blot analysis
oxifen (P, PD; C, CH; L, LIF; and E, Epiblastin A).
Cs treated for 6 days with the indicated inhibitors as measured by FACS (the
lls, EpiSCs, and ESCs. The gene expression levels are normalized to those of
trant EpiSCs into ESCs. See text for discussion.
the cell line, ROCK (Rho-associated protein kinase) inhibitor could be used to
ensure higher cell survival after single-cell dissociation with Accutase. The
next day, the EpiSC medium was replaced by the conversion medium. If not
otherwise indicated, the conversion medium consisted of MEF-conditioned
EpiSC medium containing 2 mM TR or Epiblastin A without additional bFGF.
Higher concentrations of the compounds (>5 mM) were cytotoxic and
increased cell death during conversion. The cells were cultured in the conver-
sion medium for 8 days, and after the first 3 days, the medium was changed
daily. OCT4-GFP-positive colonies usually started to appear on day 6. On
day 8, the cells were dissociated with trypsin and replated at low density on
MEF feeder cells or on a gelatin-coated cell culture dish in standard ESC me-
dium supplemented with PD to allow for single-colony formation. For the first
three to five passages, the newly formed ESC-like colonies were manually
selected, dissociated with trypsin, and replated in a new culture dish.
Flow Cytometry
For fluorescence-activated cell sorting (FACS) and analysis, cell colonies were
dissociated into single cells, as described earlier, resuspended in the corre-
sponding culture medium at a cell density of approximately 5 3 106 cells per
milliliter, and then analyzed using a FACSAria Cell Sorter (BD Biosciences).
Luciferase Assay
For quantifying relative Oct4 enhancer activity, the PE and the DE were PCR
amplified from aGOF18 plasmid (Yeomet al., 1996) and cloned into pGL3-Pro-
moter (Promega). ESCs, EpiSCs, TR-GOF18, and TR/PD-converted cells were
grown under feeder-free conditions and transfected using Lipofectamine
2000. All cells were seeded as single cells following Amaxa nucleofection
(2 million cells, 4 mg DNA, and program A-23) and assayed after 2 days.
Values were normalized to the renilla and the empty vector signals.
Western Blot
Western blot analyses were performed following a standard procedure. Pro-
teins were separated by SDS-PAGE and transferred onto nitrocellulose mem-
branes. The membranes were incubated with the antibodies raised against
phospho-S33/S37/T41-BCATENIN (Cell Signaling Technology [CST], #9561),
phospho-S465/467-SMAD2 (CST, #3101), SMAD2/3 (CST, #3102), p-ERK
(CST, #4370), ERK (CST, #9102), BCATENIN (BD Biosciences, C19220-050),
phospho-STAT3 (Santa Cruz Biotechnology, sc-8059), and STAT3 (Santa
Cruz, sc-482). Protein bands were visualized using ECL Prime Western Blot-
ting Detection Reagent (GE Healthcare).
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